Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lestaurtinib in JAK2 V617F+ PV or ET
NCT00586651Phase 2Completed
- Sponsor
- Cephalon, Inc.
- Start
- Dec 2007
- Primary completion
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lestaurtinib in polycythemia vera (PV) and essential thrombocythemia (ET), sponsored by Cephalon, Inc. Primary endpoint: Reduction in the JAK2 V617F allele burden at 18 weeks. Started Dec 2007; status: completed.
02
Drugs
lestaurtinib
03
Conditions
polycythemia vera (PV)essential thrombocythemia (ET)
Beyond the preview
Go deeper on NCT00586651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00586651.